Business, Drugs and Pharmaceuticals, Free News Articles

A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients

PARK CITY, Utah -- Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients' lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.

As a leading cause of death in infected patients, SARS-CoV-2 coronavirus-induced respiratory system damage in Covid-2 disease presents a significant and growing cause for concern worldwide. Based on the ability of PhenT to protect brain cells in neurological disorders, Aristea expects PhenT to shield lung cells and prevent COVID-19 patient's progressing into Silent Hypoxia, In Silent hypoxia insufficient oxygen reaches the blood as it passes through the lungs. It is a complication in COVID-19 that may require oxygen administration, intubation to allow machine-controlled breathing for patients associated with poor outcomes, and lead to death.


Coronavirus-induced respiratory system damage occurs even in persons who are not obviously symptomatic or asymptomatic but infected with SARS-CoV-2 coronavirus.

In healthy persons, lipids and proteins protect the alveoli - tiny air sacs in the lungs. These lipoproteins protect the alveoli from collapsing and failing to inflate during inhalation. In lungs battling COVID-19, viral induced damage removes the lipid and protein protection of alveoli Alveolar cells collapse and no longer adequately oxygenate the blood of the patient. Patients with this complication rapidly further damage lung tissue by overstretching with inspiration or ventilation. This risk requires an intervention to prevent progression in Silent Hypoxia.


PhenT has been shown to block cell dysfunction and death in cultured cells and in five animal models of head trauma, stroke, Alzheimer's disease and nerve gas toxicity. For COVID-19, this protection could extend alveolar cellular function, maintaining their lipoprotein production in alveoli. This action raises the functioning capacity of the lung to maintain oxygen saturation of blood. With this protection of alveoli, lung structures are saved from overstretching and succumbing to the damage observed in progressive SARS-Cov-2 virus infections.

About Aristea Translational Medicine Corp.

Aristea Translational Medicine Corp. is a Utah-based small business. Since its incorporation in 2000, with others located at the National Institute on Aging, NIH, and at U.S., Canadian, and U.K. universities, Aristea has investigated the sources of failures in therapeutic drug developments and methods for overcoming unnecessary failures.

Beginning in 2010, with investigators at the National Institute on Aging, Aristea turned its expertise in drug development to clinical pharmacological research that has led to the use of PhenT and its proposed applications for preventing cell dysfunction and death in COVID-19 disease.

With the support of Aristea and a $4 million, five-year grant from the National Institute of Aging, collaborators at the University of Southern California, U.S. and at the University of Exeter, U.K. are carrying out clinical trials testing PhenT as a treatment to arrest progression in Alzheimer's disease. Aristea has PhenT patents and patents pending and emphasizes that this is an opportunity announced only to facilitate empirical evaluation.

Learn more:

Aristea Translational Medicine Corp., 3435 Cedar Drive, Park City UT 84098

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif. -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

During the Phase 1b trial, ROKiT Pharma's goal will be to determine the safety and tolerability of the drug in humans, as well as understand the pharmacokinetic and pharmacodynamic properties. If ROK-001 gains IND approval, ROKiT Pharma would like to open its first clinical trial during the summer of 2020. Discussions are currently underway with two prominent hospitals for this trial.

"The University of Sydney found the naturally occurring compounds on Kangaroo Island, we then completed our multiyear process of developing the synthetic processes and patenting the compound and related analogs," said Dean Becker, chairman and CEO of ROKiT Pharma and globally recognized leader in IP strategy. "Our plan is to produce large quantities of the drug - enough for universal need - so that we can really help people combat this disease through more natural sources. Unleashing nature is our goal - we want to provide these potentially life prolonging drugs, in oral pill form, at a projected cost under $1,500 per month."

The patented chemical platform of ROKiT Pharma's key drugs have unprecedented in vitro and in vivo efficacy on 29 major types of cancer (intriguingly, showing activity on p53, AP-1, and NF-kB). Importantly, selective toxicity of ROK-001 on cancer cells rather than non-neoplastic (healthy) cell lines account for its' high therapeutic index, while safety profile evaluations confirm that the compound exerts no genotoxicity nor cardiotoxicity.

Given these results, ROKiT Pharma narrowed its focus for its' first clinical trial to some of the worst cancers that have no current cure - pancreatic and brain (specifically Glioblastoma Multiforme and patients who have had metastases to the brain from other organs).

"Once ROKiT Pharma is able to get FDA approval in one adult cancer type, we plan to divert our focus to childhood cancers," said John Paul DeJoria, ROKiT co-founder and founder of Paul Mitchell Systems and Patron Tequila. "As ROKiT continues to grow globally, we are continuing to add companies that really fulfill our humanitarian goals. Success unshared is failure."

The naturally derived anticancer compounds used to create ROK-001 were discovered through the propolis of Ligurian honey bees only found on Kangaroo Island, which lies off the mainland of South Australia. Propolis is a mixture of beeswax, saps and resins.

In animal studies, ROK-001 demonstrated great efficacy in a multitude of cancer models including pancreatic, melanoma, kidney, bladder, and breast, some in as early as seven days post-oral treatment. Aside from efficacy information, ROK-001 was specifically formulated for oral delivery that not only demonstrated nice biodistribution, but it also revealed that ROK-001 can cross the blood-brain barrier in mice. This discovery led to the decision to target brain cancers.

ROKiT Pharma hopes to fast track this relatively low-toxicity drug for patients with the most deadly cancers. With any proven efficacy in the Phase 1b clinical trial, the FDA may allow an immediate Phase 2 trial to start with an expanded cohort and patient population.

Upon IND approval of ROK-001, the company plans to make the drug available for "Compassionate Use" as is now allowed under the "Right To Try Act" that President Trump signed in 2018.

ROKiT Pharma is presently designing and planning a manufacturing facility (or contract manufacturing facility) in Puerto Rico to act as an established hub for global distribution.

"As the ROKiT brand's awareness continues to grow through our global sports sponsorships - ROKiT Williams Racing Formula 1, ROKiT Venturi Racing Formula E, the Houston Rockets, the Las Vegas Raiders - we are elated to be aggressively entering the pharmaceutical marketplace," said Jonathan Kendrick, co-founder of ROKiT.

The company is optimistic that ROK-001 will move straight into at least one Phase 2 trial and is currently adding philanthropic investors to its capital base.

If there is interest in learning more about ROKiT Pharma or for philanthropic inquiries, please contact for further information.

About ROKiT Pharma

ROKiT Pharma is a late stage preclinical pharma company focusing its research efforts on cancer. The corporation has an extensive global intellectual property portfolio. Research was developed at and in conjunction with the University of Sydney.

Additional information (*new site under construction Q2/2020):

Media Contact:
Kristyn Clark
Senior PR Manager
ROKiT Pharma
Tel: (805) 231-1572

*LOGO link for media:

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Manufacturing, Product Launches

Boothwyn Pharmacy in Kennett Square Now Manufacturing Hand Sanitizer

KENNETT SQUARE, Pa. -- Boothwyn Pharmacy, a PCAB-accredited compounding pharmacy located mere minutes from the heart of Kennett Square, Pennsylvania, has dedicated resources to manufacture hand sanitizer.

In response to the rising number of COVID-19 cases, the medical supply shortages created by it, and the increase in reports of homemade hand sanitizers, the FDA has given approval to accredited compounding pharmacies to commence the production of hand sanitizers.

On March 14, 2020, the FDA released new guidance for industry policy regarding the "Temporary Compounding of Certain Alcohol-Based Hand Sanitizers During the Public Health Emergency" to address the need for safe and properly prepared hand sanitizing products that have become commercially unavailable.

Committed to the health and wellbeing of the community, Boothwyn Pharmacy produced its first batch of hand sanitizer on Monday, March 23. This product was compounded in accordance with guidelines set by the FDA and recommendations from the World Health Organization. It contains 75% Isopropyl Alcohol and was made in a state-of-the-art PCAB and NABP-accredited laboratory.

Louis Micolucci, the CEO of Boothwyn Pharmacy, donated the first batch to the Kennett Square and East Marlborough Township police departments and the Longwood Fire Company to ensure the safety of local first responders.

Their hand sanitizer is now available online at and can be shipped right to your door.

It is also available at both of their locations: Boothwyn Apothecary in Boothwyn, Pennsylvania, and Boothwyn Pharmacy in Kennett Square, Pennsylvania. Curbside service is available and they will bring hand sanitizer right to your car. Please call ahead to ensure hand sanitizer will be ready for you upon arrival.

About Boothwyn Pharmacy:

Helping the community is not simply an utterance of words for the Boothwyn Pharmacy family, but rather a philosophy that has been engrained in each and every member since their doors first opened in 1933.

Boothwyn Apothecary
2341 Chichester Ave
Boothwyn, PA 19061

Boothwyn Pharmacy
221 Gale Lane
Kennett Square, PA 19348

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Insurance

EPIC Continues Expansion of Employee Benefits Practice with a new Pharmacy Practice Leader

NEW YORK, N.Y. -- EPIC Insurance Brokers and Consultants, a retail property, casualty insurance brokerage and employee benefits consultant, announced today they are continuing to expand their employee benefits resources with the addition of a new Pharmacy Practice Leader, Bob Eisendrath. We are also pleased to announce that we have promoted Craig Hasday to President, National Employee Benefits Practice leader and Cindy Santangelo to National Voluntary Benefits Practice Leader.

Bob Eisendrath brings a strong background in pharmacy benefit management. He brings experience both in sales and national account management, with CVS Caremark for 20 years where he was most recently Area Vice President for Coalition Business. "The addition of Bob will further strengthen our Pharmacy consulting practice as he leads the team through the rapidly changing legislative and therapeutic landscape as our clients grapple with increasing pharmacy prices, one of the most problematic components of escalating cost," said Craig Hasday, National Employee Benefits Practice Leader.

Craig Hasday has been promoted to President, National Employee Benefits Leader. Said Steve Denton, President, EPIC Holdings, "For the past eighteen months, Craig has led EPIC's National Employee Benefits Operations Board. In that role, Craig has worked closely with the geographic employee benefits leaders and has done an incredible job bringing our national teams together."

During this time, EPIC has seen increased communication and enhancements across the board in service offerings for our clients. Further, EPIC has seen great improvement in revenue growth, profitability, and integration of its vast employee benefits platform. Employee Benefits revenue of over $170 million which represents over 20% of EPIC's retail revenue.

Promoting Cindy Santangelo to the new national role as lead of EPIC's Voluntary Benefits practice highlights EPIC's growing focus on the changing workplace dynamic of offering personalized benefits. Santangelo has been with EPIC for 12 years and spent the past 5 years building and growing the Voluntary Benefits practice within EPIC's national Employee Benefit platform. She brings a wealth of knowledge to her role in employee paid worksite benefits consulting as she fully understands how to create a customized program to meet individualized needs.

"We are fortunate to have someone with her expertise on our team to support our clients and other EPIC consultants," said John Gaffney, VP. National Employee Benefits Operations.

About EPIC Insurance Brokers & Consultants

EPIC is a unique and innovative retail property and casualty and employee benefits insurance brokerage and consulting firm. EPIC has created a values-based, client-focused culture that attracts and retains top talent, fosters employee satisfaction and loyalty and sustains a high level of customer service excellence.

EPIC team members have consistently recognized their company as a "Best Place to Work" in multiple regions and as a "Best Place to Work in the Insurance Industry" nationally.

EPIC now has more than 2,600 team members operating from more than 70 offices across the U.S., providing Property and Casualty, Employee Benefits, Specialty Programs and Private Client solutions to EPIC clients.

With run rate revenues greater than $730 million, EPIC ranks among the top 15 retail insurance brokers in the U.S. Backed and sponsored by Oak Hill Capital Partners, the company continues to expand organically and through strategic acquisitions across the country. For additional information, please visit

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Drugs and Pharmaceuticals, Free News Articles

iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting

STONY BROOK, N.Y. -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

ASH abstracts are now available at

Oral Presentation:

Title: First-in-Human Trial of BCMA-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction
Session: 721. Abstract Number: 38
Saturday, December 7, 2019: 7:45 a.m.
Valencia BC (W415BC), Level 4 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162353

Poster Presentation:

Title: First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma
Session: 626. Abstract Number: 2881
Sunday, December 8, 2019, 6 p.m. to 8 p.m.
Hall B, Level 2 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162340

About BCMA-CD19 cCAR therapy

BCMA-CD19 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressing on a T-cell, directed against the surface proteins BCMA and CD19. The diseases treated by BCMA-CD19 cCAR could include autoimmune disorders, and organ rejection. BCMA is expressed in plasma cells, while CD19 is related to B-cells. BCMA-CD19 cCAR is designed to completely remove antibody-producing "roots", plasma cells and B cells, and then re-set the immune system for treating antibody-mediated autoimmune disorders or organ rejections.

BCMA-CD19 cCAR is also aimed to treat multiple myeloma, a challenging disease due to the heterogeneity of myeloma cells, which renders single-antigen targeting CAR T-cell therapy ineffective. BCMA-CD19 cCAR is proposed to target both bulky myeloma cells expressing BCMA, and myeloma stem cells expressing CD19 to effectively eradicate the disease.

About CD4-specific CAR (CD4 CAR) therapy

CD4-specific CAR with a safety switch is designed to treat peripheral T cell lymphoma as CD4 is uniformly expressed on most mature T cell lymphoma, and transient depletion of CD4 is expected. The diseases treated by CD4 CAR could include peripheral T-cell lymphoma (NOS), Sezary syndrome/cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T cell lymphoma, T-cell prolymphocytic leukemia, T-cell acute lymphoblastic leukemia/lymphoma and T-cell large granular lymphocytic leukemia. Most of these diseases are difficult to treat, with dismal prognoses. An IND has been approved for iCell Gene Therapeutics to initiate a multi-site clinical trial at Stony Brook University Hospital and University of Louisville.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Clinical studies on our CARvac, T-cell targeted CARs, Compound CARs, Non-gene edited universal CARs and C-TPS1 (depletion of TREG, blockage of PD-L1 pathways and stimulation of tumor infiltrating lymphocytes) for solid tumors are ongoing in the US and in China.

For more information, please visit

Media and Investors
Kevin Pinz
Tel: (631) 538-6218

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

American Medical Marijuana Physicians Association’s 2019 Annual Meeting Hosted Over 300 Attendees and Physicians

ORLANDO, Fla. -- The American Medical Marijuana Physicians Association (AMMPA) held their 3rd Annual Conference on October 4-6 at the Hilton Orlando Lake Buena Vista. More than 300 medical marijuana practitioners and physicians from across the nation and other countries around the world attended the 3-day conference.

The meeting provided educational presentations, networking and panel discussions with thought-leaders dedicated to the research and utilization of medical cannabis to improve the health of their patients. AMMPA is the largest medical cannabis association in the world, boasting the highest membership base for an organization of its kind. The AMMPA Annual Conferences are dedicated to medical research and education, presenting on the health benefits of medical cannabis.

This year, the AMMPA Annual Conference featured Keynote Speaker Nikki Fried, the 12th Florida Commissioner of Agriculture and Consumer Services. Commissioner Fried is a strong advocate for medical marijuana and created a Medical Marijuana Advisory Committee this past Summer.

A number of recognized medical marijuana physician leaders attended and over 20 nationally recognized speakers participated in lectures and panel discussions. In addition to Commissioner Fried, our second Keynote Speaker was Professor Hinanit Koltai, PhD, a Senior Research Scientist from the Volcani Center in Israel. Our panel also featured Jade Green, CEO of Jade Green Consulting, an all-female canna-business consultancy, based out of Los Angeles.

The faculty engaged the audience in a series of lectures and panel discussions on the recent literature relevant to the benefits of cannabis in addressing medical conditions such as Cancer, Seizure Disorders, Anxiety, HIV, Chronic Pain, Migraines, and Autism. The Annual Conference was supported by a host of medical cannabis industry leaders including our Premier Emerald Sponsor, Leafly.

About the American Medical Marijuana Physicians Association (AMMPA):
The American Medical Marijuana Physicians Association is a membership driven association, focusing on providing physicians with the resources they need to safely and effectively utilize medical marijuana recommendations as an alternative treatment modality for their patients. AMMPA serves as a physician advocate helping to outline practice risks and benefits, educational requirements, compliance issues, and aggregates its members to allow for a unified voice representing all physicians currently interested in cannabinoid medicine. Our members are leaders in the nation that provide expertise to the public regarding research, education, speaking engagements, seminars, and industry recommendations.

American Medical Marijuana Physicians Association, 1215 E. Robinson Street, Orlando, FL 32801.


Savara Hastings

*Photo Caption - Pictured (L-R): Jade Green, CEO Jade Green Consulting; Savara Hastings, AMMPA Executive Director; Dr. Jaime Snarski, AMMPA Board Member; Megan Zalonka, AMMPA Communications Director.

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Hospitals and Nursing, NonProfit and Charities

C Diff Foundation Raises Clostridioides difficile Awareness in St. Louis on Nov. 6-7 at 7th Annual International Conference and Health EXPO

ST. LOUIS, Mo. -- C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues on November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel, 1973 Craigshire Road, St. Louis, MO 63146; Telephone: +1 (314) 434-0100.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit:

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by an independent patient advocacy Grant from Merck & Co., Inc., and the members of the C Diff Foundation are truly grateful.

Attendee Paul Feuerstadt MD, FACG, AGAF stated, "The annual C Diff Foundation conference and health expo is an essential conference for me to attend, given the comprehensive presentations about epidemiology, disease state, patient experience, infection control and innovations with treatment of C. difficile. The level of detail and data presented has a wonderful balance that is understandable for someone casually interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. EST ( sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at:

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
Office: (727) 205-3922

*IMAGE link for media:

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

BioAdaptives, Inc. Announces Return to Fully Reporting and Appointment of President

LAS VEGAS, Nev. -- BioAdaptives, Inc. (OTC BB: BDPT) announced the Company's return to a fully-reporting entity, and the appointment of Mr. Robert W. Ellis as its new President, reporting to Dr. Edward E. Jacobs, Jr.

Dr. Jacobs, Director and CEO said, "We are very pleased to again be an SEC fully-reporting Company, even though when it ceased reporting on EDGAR during 2017 and 2018, the Company continued to release full disclosure data via OTC Market's alternate reporting format."

Dr. Jacobs added, "We are also pleased to announce the appointment of Mr. Robert W Ellis to our Management team. With his additional, it allows me the opportunity to spend more time on the strategic development of BioAdaptives, and to continue scientific research and advancement of a broad line of wellness products for people and animals."

"Mr. Ellis brings more than forty years of business management experience to this new assignment. He has held senior financial and operating management positions in aerospace and telecommunication public corporations, as well as private companies in both mature technology business and development-stage entities," Dr. Jacobs further added.

Mr. Ellis stated, "I am pleased to join BioAdaptives in this position and look forward to leading the Company as it emerges further from its development stage and matures into a growing successful manufacturing and distribution company. We expect to expand BioAdaptives operation through acquisitions and subsidiary entities in its current natural wellness sphere and in related fields in order to add to the Company's bottom line."

About BioAdaptives, Inc.:

BioAdaptives, Inc. is a fully-reporting, public company trading on the OTC Bulletin Board under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for human and animal consumption. Learn more at:


Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc. and its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc.'s filings with the Securities and Exchange Commission.


Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Awards and Honors, Business, Drugs and Pharmaceuticals, Free News Articles

2019 Lupus Insight Prize Awarded to Dr. Ignacio Sanz: Recognizes Studies of Harmful Immune Cells in Lupus

BOSTON, Mass. -- The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients could benefit from current drugs. Dr. Sanz is a Mason Lowance Professor of Medicine and Pediatrics and Chief of the Division of Rheumatology at Emory University School of Medicine in Atlanta, Georgia.

The award was announced June 19 at FOCIS 2019, the 19th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS). The $100,000 award recognizes a major, novel insight and/or discovery with the promise of changing thinking about lupus as well as a high probability of generating further advances in the diagnosis and treatment of the disease.

"Dr. Sanz has already made vital contributions to understanding the role of B cells in lupus," said Kenneth M. Farber, President and CEO, Lupus Research Alliance. "We very much look forward to his next advances afforded by our Lupus Insight Prize."

Dr. Sanz's discoveries were a breakthrough for understanding how certain B cells, a type of immune cell, promote lupus. B cells are key for the disease. Their normal job is to produce proteins called antibodies that protect against bacteria and viruses. But in lupus, B cells release antibodies that trigger damage to patients' own tissues. Researchers have known that some B cells must mature in specialized parts of the lymph nodes or spleen before they can make these destructive antibodies.

Dr. Sanz showed that many damaging B cells follow a different route and identified the molecular mechanisms that underpin this B cell activation pathway. He and his team were the first to apply a comprehensive characterization of these cells using cutting-edge techniques such as multidimensional flow cytometry analysis of DNA in lupus patients. They found that this group of B cells was prevalent in patients who were undergoing lupus flares, particularly African-Americans. Dr. Sanz and his colleagues also found that, in contrast to healthy subjects, the lupus B cells were ready to transform into cells that produce harmful antibodies, even in patients without active disease.

"I thank the Lupus Research Alliance for recognizing my work, and I am eager to pursue further research with the potential for improving patient treatment," said Dr. Sanz.

Researchers may be able to build on Dr. Sanz' discoveries to develop new drugs that could reduce patients' risk and severity of disease flares. The results could also help doctors identify subsets of lupus patients that are more likely to benefit from therapies that destroy B cells using existing drugs. In addition, the cellular and molecular make-up of the abnormal lupus B cells should help identify new therapeutic targets.

About Lupus

Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than 90% of people with lupus are women; lupus most often strikes during the childbearing years of 15-45. African Americans, Latin Americans, Asians and Native Americans are two to three times at greater risk than Caucasians. In lupus, the immune system, which is designed to protect against infection, creates antibodies that can attack any part of the body including the kidneys, brain, heart, lungs, blood, skin, and joints.

About the Lupus Research Alliance

The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world. The organization's stringent peer review grant process fosters diverse scientific talent who are driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the Lupus Research Alliance's Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Learn more at:

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Awards and Honors, Business, Drugs and Pharmaceuticals, Free News Articles, NonProfit and Charities

C Diff Foundation Recognizes Rebiotix CEO with 2019 ‘Above and Beyond’ Award

NEW PORT RICHEY, Fla. -- The C. Diff Foundation Board of Directors announced today that the 2019 "Above and Beyond" Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.

"We are very proud to recognize Ms. Jones with our "Above and Beyond" award," said C. Diff Foundation Founder and President, Nancy Caralla. "Lee's dedication to the entire C. diff community of patients, family members, and physicians hasn't wavered since the founding of Rebiotix in 2011. She is a true example of what can happen when focusing on patient well-being drives new approaches to healthcare."

The award will be presented by the Foundation's Vice President, Scott Battles, and Treasurer Angelo Ortiz at the Rebiotix facility.

"It's an honor to receive this award from the C. Diff Foundation," said Ms. Jones. "The purpose of starting Rebiotix was to bring the power of the microbiome to the clinic in a scientifically sound, quality-controlled way to help patients. We stand with the Foundation in believing that patient well-being should be at the core of all that we do, from clinical trials to exploring new scientific landscapes within the microbiome space."

About the C Diff Foundation:

The C Diff Foundation is a non-profit, 501(c)(3) organization established in 2012. It is comprised of 100% volunteering professionals dedicated to supporting public health through education and advocacy for C. difficile infection prevention, treatments, environmental safety and support world-wide. The Foundation's CEO and founder is a nurse inspired to create the foundation after witnessing the loss of her father to CDI, as well as suffering from the infection herself. The C Diff Foundation members, with their volunteer patient advocates, successfully "raise C. diff awareness" locally and in over fifty-six (56) countries and host a U.S. nation-wide hotline (1-844-FOR-CDIF) to support healthcare providers, patients and families through the difficulties of a C. diff infection. Learn more:

About Rebiotix Inc.:

Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.

Rebiotix's clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy(tm) platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit

Twitter: @cdiffFoundation #CdiffInfection #Clostridiumdifficile @Rebiotix

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.